Determination of five mTOR inhibitors in human plasma for hepatocellular carcinoma treatment using QuEChERS-UHPLC-MS/MS

被引:1
作者
Wang, Ting [1 ]
Jin, Chengcheng [1 ]
Jiang, Wen [1 ]
Zhao, Tingting [2 ]
Xu, Yanmei [3 ]
Li, Hui [3 ]
机构
[1] Hebei Univ Sci & Technol, Coll Chem & Pharmaceut Engn, Shijiazhuang, Peoples R China
[2] Hebei Med Univ, Coll Pharm, Shijiazhuang 050000, Peoples R China
[3] Hebei Inst Drug & Med Device Inspect, Shijiazhuang, Peoples R China
关键词
Mammalian target of rapamycin inhibitors; UHPLC-MS/MS; QuEChERS; Human plasma; CYCLOSPORINE-A; EVEROLIMUS; TACROLIMUS; EXTRACTION; SIROLIMUS;
D O I
10.1016/j.jpba.2023.115652
中图分类号
O65 [分析化学];
学科分类号
070302 ; 081704 ;
摘要
A fast and reliable QuEChERS (Quick, Easy, Cheap, Effective, Rugged, and Safe) method for pre-processing combined with Ultra - high performance liquid chromatography - tandem mass spectrometry (UHPLC-MS/MS) was established for the analysis of five mammalian rapamycin target protein (mTOR) inhibitors (vistusertib, AZD8055, pictilisib, everolimus, temsirolimus)in human plasma. Extraction was achieved by addition of acetonitrile to the sample followed by anhydrous magnesium sulfate and 30 mg C18 for salting out and purification, respectively. MTOR inhibitors were detected using selective response monitoring (SRM) under positive ion electrospray mode. Vistusertib, AZD8055 and pictilisib showed good linearity with a range of 1-80 ng/ml, Additionally, the concentration of everolimus and temsirolimus was 2.5-200 ng/ml and10-800 ng/ml, respectively. The linear correlation coefficient (R2) of each analysis was & GE; 0.9950. The limit of detection (LOD) and Limit of Quantitation (LOQ) were 0.015-0.75 ng/ml and 1-10 ng/ml, respectively. This method showed a high accuracy with high recovery rate and excellent stability. This method is fast, accurate and reliable, suitable for quantitative detection of mTOR inhibitors in human plasma.
引用
收藏
页数:10
相关论文
共 33 条
  • [21] Effective use of liquid chromatography-mass spectrometry (LC/MS) in the routine clinical laboratory for monitoring sirolimus, tacrolimus, and cyclosporine
    Poquette, MA
    Lensmeyer, GL
    Doran, TC
    [J]. THERAPEUTIC DRUG MONITORING, 2005, 27 (02) : 144 - 150
  • [22] Conversion to Everolimus in Maintenance Liver Transplant Patients: A Multicenter, Retrospective Analysis
    Saliba, Faouzi
    Dharancy, Sebastien
    Lorho, Richard
    Conti, Filomena
    Radenne, Sylvie
    Neau-Cransac, Martine
    Hurtova, Monika
    Hardwigsen, Jean
    Calmus, Yvon
    Dumortier, Jerome
    [J]. LIVER TRANSPLANTATION, 2011, 17 (08) : 905 - 913
  • [23] Validation of a rapid liquid chromatography tandem mass spectrometric method for the quantitative analysis of vistusertib
    Scott, Susan C.
    Anders, Nicole M.
    Scardina, Morgan
    Hann, Christine L.
    Rudek, Michelle A.
    [J]. JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2022, 208
  • [24] Simultaneous determination of multiclass pesticide residues in human plasma using a mini QuEChERS method
    Srivastava, Anshuman
    Rai, Satyajeet
    Sonker, Ashish Kumar
    Karsauliya, Kajal
    Pandey, Chandra Prabha
    Singh, Sheelendra Pratap
    [J]. ANALYTICAL AND BIOANALYTICAL CHEMISTRY, 2017, 409 (15) : 3757 - 3765
  • [25] An isotope dilution LC-MS/MS based candidate reference method for the quantification of cyclosporine A, tacrolimus, sirolimus and everolimus in human whole blood
    Taibon, Judith
    van Rooij, Milou
    Schmid, Rupert
    Singh, Neeraj
    Albrecht, Eva
    Wright, Jo Anne
    Geletneky, Christian
    Schuster, Carina
    Moerlein, Sophie
    Vogeser, Michael
    Seger, Christoph
    Pongratz, Stephan
    Kobold, Uwe
    [J]. CLINICAL BIOCHEMISTRY, 2020, 82 : 73 - 84
  • [26] Pictilisib PI3Kinase inhibitor (a phosphatidylinositol 3-kinase [PI3K] inhibitor) plus paclitaxel for the treatment of hormone receptor-positive, HER2-negative, locally recurrent, or metastatic breast cancer: interim analysis of the multicentre, placebo-controlled, phase II randomised PEGGY study
    Vuylsteke, P.
    Huizing, M.
    Petrakova, K.
    Roylance, R.
    Laing, R.
    Chan, S.
    Abell, F.
    Gendreau, S.
    Rooney, I.
    Apt, D.
    Zhou, J.
    Singel, S.
    Fehrenbacher, L.
    [J]. ANNALS OF ONCOLOGY, 2016, 27 (11) : 2059 - 2066
  • [27] Determination of olverembatinib in human plasma and cerebrospinal fluid by an LC-MS/MS method: Validation and clinical application
    Xiang, Dong
    Zhao, Tinghui
    Wang, Jue
    Cao, Yang
    Yu, Qiuxia
    Liu, Lu
    Yu, Hengyi
    Li, Xiping
    Li, Ninghong
    Yi, Yang
    Gong, Xuepeng
    [J]. JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2023, 230
  • [28] Therapeutic potential and adverse events of everolimus for treatment of hepatocellular carcinoma - systematic review and meta-analysis
    Yamanaka, Kenya
    Petrulionis, Marius
    Lin, Shibo
    Gao, Chao
    Galli, Uwe
    Richter, Susanne
    Winkler, Susanne
    Houben, Philipp
    Schultze, Daniel
    Hatano, Etsuro
    Schemmer, Peter
    [J]. CANCER MEDICINE, 2013, 2 (06): : 862 - 871
  • [29] Yeo W., 2013, ANN ONCOL, V24, DOI [10.1093/annonc/mdt202.22, DOI 10.1093/ANNONC/MDT202.22]
  • [30] Attacking the PI3K/Akt/mTOR signaling pathway for targeted therapeutic treatment in human cancer
    Yu, Le
    Wei, Jessica
    Liu, Pengda
    [J]. SEMINARS IN CANCER BIOLOGY, 2022, 85 : 69 - 94